AP2013006693A0 - Phamaceutical composition for the prolonged release of trimetazidine - Google Patents

Phamaceutical composition for the prolonged release of trimetazidine

Info

Publication number
AP2013006693A0
AP2013006693A0 AP2013006693A AP2013006693A AP2013006693A0 AP 2013006693 A0 AP2013006693 A0 AP 2013006693A0 AP 2013006693 A AP2013006693 A AP 2013006693A AP 2013006693 A AP2013006693 A AP 2013006693A AP 2013006693 A0 AP2013006693 A0 AP 2013006693A0
Authority
AP
ARIPO
Prior art keywords
trimetazidine
prolonged release
phamaceutical composition
phamaceutical
composition
Prior art date
Application number
AP2013006693A
Other languages
English (en)
Inventor
Patrick Genty
Jean-Manuel Pean
Christophe Hermelin
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013006693(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2013006693A0 publication Critical patent/AP2013006693A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2013006693A 2012-02-03 2013-01-28 Phamaceutical composition for the prolonged release of trimetazidine AP2013006693A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (1)

Publication Number Publication Date
AP2013006693A0 true AP2013006693A0 (en) 2013-01-31

Family

ID=47504206

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006693A AP2013006693A0 (en) 2012-02-03 2013-01-28 Phamaceutical composition for the prolonged release of trimetazidine

Country Status (48)

Country Link
US (1) US10117838B2 (pl)
EP (1) EP2623096B1 (pl)
JP (1) JP6338818B2 (pl)
KR (2) KR20130090365A (pl)
CN (2) CN106924221A (pl)
AP (1) AP2013006693A0 (pl)
AR (1) AR089861A1 (pl)
AU (1) AU2013200481B2 (pl)
BR (1) BR102013002524B1 (pl)
CA (1) CA2805471C (pl)
CL (1) CL2013000336A1 (pl)
CO (1) CO6720159A1 (pl)
CR (1) CR20130037A (pl)
CU (1) CU24157B1 (pl)
CY (1) CY1121696T1 (pl)
DK (1) DK2623096T3 (pl)
DO (1) DOP2013000024A (pl)
EA (1) EA030227B1 (pl)
EC (1) ECSP13012415A (pl)
ES (1) ES2735053T3 (pl)
FR (1) FR2986431B1 (pl)
GE (1) GEP20156342B (pl)
GT (1) GT201300032A (pl)
HR (2) HRP20130082A2 (pl)
HU (1) HUE043942T2 (pl)
IL (1) IL224495B (pl)
JO (1) JO3505B1 (pl)
LT (1) LT2623096T (pl)
MD (1) MD4622C1 (pl)
MX (1) MX363302B (pl)
MY (1) MY162599A (pl)
NI (1) NI201300014A (pl)
PE (1) PE20131119A1 (pl)
PH (1) PH12013000031A1 (pl)
PL (1) PL2623096T3 (pl)
PT (1) PT2623096T (pl)
PY (1) PY1303869A (pl)
RO (1) RO128004A3 (pl)
RS (2) RS20130034A1 (pl)
RU (1) RU2621128C2 (pl)
SG (1) SG192386A1 (pl)
SI (1) SI2623096T1 (pl)
SV (1) SV2013004396A (pl)
TR (1) TR201906390T4 (pl)
TW (1) TWI508755B (pl)
UA (1) UA118742C2 (pl)
UY (1) UY34595A (pl)
WO (1) WO2013114053A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2675002T3 (es) * 2014-04-08 2018-07-05 Dow Global Technologies Llc Dispersión que comprende un éter de celulosa esterificado
CA3044270A1 (en) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법
WO2025068837A2 (en) * 2023-09-26 2025-04-03 Zim Laboratories Limited A novel extended release pharmaceutical composition of trimetazidine or salt thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (pl) * 1960-10-20
FR2490963B1 (fr) 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
ATE442852T1 (de) * 2000-10-05 2009-10-15 Usv Ltd Trimetazidine enthaltendes arzneimittel mit verzögerter wirkstoffabgabe und verfahren zur herstellung
EP1448173A2 (en) * 2001-11-21 2004-08-25 Themis Laboratories Private Limited A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
MX350380B (es) * 2006-05-09 2017-09-05 SpecGx LLC Formas de dosificacion solida de liberacion modificada en el orden de cero.
CN100571703C (zh) * 2006-12-20 2009-12-23 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
WO2009060952A1 (ja) * 2007-11-09 2009-05-14 Mitsubishi Tanabe Pharma Corporation 新規製剤
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
JP2012515757A (ja) * 2009-01-20 2012-07-12 マイクロ ラブス リミテッド トリメタジジンの放出調節固形薬剤組成物及びその製造方法
ES2567722T3 (es) * 2009-01-30 2016-04-26 Lupin Limited Composiciones farmacéuticas de trimetazidina
EP2408437A1 (en) * 2009-03-18 2012-01-25 Evonik Röhm GmbH Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
ES2508490T3 (es) * 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Also Published As

Publication number Publication date
RS20130034A1 (sr) 2013-10-31
MD4622B1 (ro) 2019-03-31
PH12013000031B1 (en) 2014-09-22
KR101918211B1 (ko) 2018-11-14
KR20150102922A (ko) 2015-09-09
ECSP13012415A (es) 2014-09-30
TW201332591A (zh) 2013-08-16
GEP20156342B (en) 2015-08-10
RS58752B1 (sr) 2019-06-28
SV2013004396A (es) 2013-06-05
MD4622C1 (ro) 2019-10-31
UY34595A (es) 2013-09-02
HRP20130082A2 (hr) 2013-08-31
RO128004A0 (ro) 2012-12-28
MX363302B (es) 2019-03-20
ES2735053T3 (es) 2019-12-13
PY1303869A (es) 2015-11-02
AR089861A1 (es) 2014-09-24
IL224495B (en) 2020-08-31
CU20130016A7 (es) 2014-10-02
HRP20191072T1 (hr) 2019-11-01
WO2013114053A2 (fr) 2013-08-08
GT201300032A (es) 2014-06-09
MD20130005A2 (ro) 2013-07-31
SI2623096T1 (sl) 2019-06-28
CY1121696T1 (el) 2020-07-31
PH12013000031A1 (en) 2014-09-22
FR2986431A1 (fr) 2013-08-09
CO6720159A1 (es) 2013-07-31
EA201300079A3 (ru) 2013-11-29
CU24157B1 (es) 2016-03-31
TR201906390T4 (tr) 2019-05-21
RU2013104252A (ru) 2014-08-10
PT2623096T (pt) 2019-05-30
TWI508755B (zh) 2015-11-21
CR20130037A (es) 2013-09-18
WO2013114053A3 (fr) 2013-12-19
CN106924221A (zh) 2017-07-07
CL2013000336A1 (es) 2014-07-18
CA2805471C (fr) 2018-05-01
DOP2013000024A (es) 2014-07-15
DK2623096T3 (da) 2019-07-15
MX2013001118A (es) 2013-08-27
BR102013002524A2 (pt) 2014-09-09
JO3505B1 (ar) 2020-07-05
SG192386A1 (en) 2013-08-30
MY162599A (en) 2017-06-30
EA201300079A2 (ru) 2013-07-30
EP2623096B1 (fr) 2019-04-03
PE20131119A1 (es) 2013-10-12
UA118742C2 (uk) 2019-03-11
US20130202710A1 (en) 2013-08-08
AU2013200481A1 (en) 2013-08-22
CA2805471A1 (fr) 2013-08-03
JP2013159609A (ja) 2013-08-19
NI201300014A (es) 2013-05-13
PL2623096T3 (pl) 2019-08-30
EA030227B1 (ru) 2018-07-31
HUE043942T2 (hu) 2019-09-30
BR102013002524B1 (pt) 2020-02-04
CN103239425A (zh) 2013-08-14
US10117838B2 (en) 2018-11-06
EP2623096A2 (fr) 2013-08-07
NZ606550A (en) 2014-09-26
AU2013200481B2 (en) 2015-01-22
RU2621128C2 (ru) 2017-05-31
JP6338818B2 (ja) 2018-06-06
KR20130090365A (ko) 2013-08-13
LT2623096T (lt) 2019-05-10
EP2623096A3 (fr) 2013-10-23
FR2986431B1 (fr) 2017-03-17
RO128004A3 (ro) 2013-08-30

Similar Documents

Publication Publication Date Title
ZA201503603B (en) Composition for immediate and extended release
GB201217441D0 (en) Composition
GB201200707D0 (en) Composition
AP3681A (en) Modified release formulations for oprozomib
SG11201500544SA (en) Composition for agent for external use
EP2878295A4 (en) COMPOSITION
GB2498803B (en) Composition
GB201218954D0 (en) Composition
AP2013006693A0 (en) Phamaceutical composition for the prolonged release of trimetazidine
GB201222275D0 (en) Composition
GB201202420D0 (en) Radiotracer compositions
GB201219657D0 (en) Composition
GB201206035D0 (en) Composition
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201218195D0 (en) Composition
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
GB201202183D0 (en) Contraceptive compounds
GB201211308D0 (en) Compounds for use
IL238999A0 (en) Violet type fragrances
GB201223526D0 (en) Composition
GB201223224D0 (en) Composition
GB201221334D0 (en) Composition